SilverHawk Plaque Excision System for Treatment of Lower Extremity Peripheral Arterial Disease.ev3 Inc. (NASDAQ: EVVV) today announced that the first patients were recently enrolled in the DEFINITIVE LE post-market study. DEFINITIVE LE is a prospective, multi-center, single-arm study to evaluate the intermediate and long-term effectiveness of stand-alone SilverHawk® Plaque Excision therapy for endovascular treatment of lower extremity peripheral arterial disease (PAD). Stuart Harlin, M.D., of Sacred Heart Hospital in Pensacola, Florida and Prakash Makam, M.D., of Community Hospital in Munster, Indiana enrolled the first two patients.To view Multimedia News Release, go to http://www.prnewswire.com/mnr/ev3/38145/

Genre: News Videos

by: comments